Falls and physical function in older patients with Benign Paroxysmal Positional Vertigo (BPPV): findings from a placebo controlled, double blinded randomized control trial (RCT) investigating efficacy of vitamin D treatment in lowering the recurrence rate of BPPV.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

Primary outcome: does vitamin D supplementation and dietary interventions in combination with standard care impact falls, fear of falling and function in patients with BPPV.

Why It Was Studied

Benign Paroxysmal Positional Vertigo (BPPV) is the commonest cause of vertigo in older adults.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults, older adults and people over 80, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Random assignment meant chance, not the researchers, decided who got Vitamin D, K2, Magnesium and Zinc and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

What Was Measured

Topics PubMed links to this paper include Benign Paroxysmal Positional Vertigo, Vitamin D, Accidental Falls, Recurrence and Dietary Supplements.

The authors tagged it with the keywords BPPV, Fear of falling and Older adults.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2025 (Aging clinical and experimental research), a journal based in Germany.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.